OPTIC – Treatment of Graves’ Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in a Clinical Study
OPTIC – Treatment of Graves’ Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in a Clinical Study
To evaluate the efficacy and safety of Teprotumumab (a fully human monoclonal antibody inhibitor of the insulin-like growth factor 1 receptor) in subjects with moderate-to-severe active Thyroid Eye Disease (TED).
Teprotumumab alters the course of debilitating TED and will potentially spare patients from invasive orbital decompressive procedures. Unfortunately, the cost of q3weekly infusions x 8 costs $343,000. It is therefore not a reasonable option for the general TED population.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020 Jan 23;382(4):341-352.
